Masao Nakagawa

11PUBLICATIONS
29CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyMolecular targetsPredictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 13, 2026
PLK1 inhibition enhances Brentuximab vedotin efficacy in CD30-positive T-cell lymphoma via spindle assembly checkpoint activation.

|Nov 12, 2025
The IL-1R and NFKBIZ pathway mediates immunoregulatory responses and immunotherapy efficacy in anaplastic large cell lymphoma.

Wei Wei, Zhihui Song, Yajun Wang

|Nov 10, 2025
Correction: Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma.

Keito Suto, Norio Takei, Keito Yokoyama

|May 02, 2025
TP53 and CDKN2A alterations define a poor prognostic subgroup in patients with nodal T follicular helper cell lymphoma.

Yuta Ito, Joji Shimono, Keisuke Kawamoto

|Oct 21, 2024
Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma.

Keito Suto, Norio Takei, Keito Yokoyama

|Dec 24, 2023
Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma.

Masahiro Chiba, Joji Shimono, Keito Suto

Pageof 2

Frequent Collaborators

7 joint publications

Yibin Yang

7 joint publications

Takanori Teshima

6 joint publications

Masahiro Chiba

4 joint publications

Keito Suto